Rituximab in patients with primary CNS lymphoma (HOVON 105/ALLG NHL 24): a randomised, open-label, phase 3 intergroup study

Jacoline Bromberg; S Issa; Katerina Bakunina; MC Minnema; T Seute; M Durian; G Cull; HC Schouten; WBC Stevens; JM Zijlstra; JW Baars; M Nijland; KD Mason; A Beeker; Martin van den Bent; M Beijert; M Gonzales; D Jong; Jeanette Doorduijn

doi:10.1016/s1470-2045(18)30747-2

Rituximab in patients with primary CNS lymphoma (HOVON 105/ALLG NHL 24): a randomised, open-label, phase 3 intergroup study

Jacoline Bromberg, S Issa, Katerina Bakunina, MC Minnema, T Seute, M Durian, G Cull, HC Schouten, WBC Stevens, JM Zijlstra, JW Baars, M Nijland, KD Mason, A Beeker, Martin van den Bent, M Beijert, M Gonzales, D Jong, Jeanette Doorduijn

Research output: Contribution to journal › Article › Academic › peer-review

113 Citations (Scopus)

Original language	Undefined/Unknown
Pages (from-to)	216-228
Number of pages	13
Journal	Lancet Oncology
Volume	20
Issue number	2
DOIs	https://doi.org/10.1016/s1470-2045(18)30747-2
Publication status	Published - 2019

Access to Document

10.1016/s1470-2045(18)30747-2

http://hdl.handle.net/1765/115253

Cite this

Bromberg, J., Issa, S., Bakunina, K., Minnema, MC., Seute, T., Durian, M., Cull, G., Schouten, HC., Stevens, WBC., Zijlstra, JM., Baars, JW., Nijland, M., Mason, KD., Beeker, A., van den Bent, M., Beijert, M., Gonzales, M., Jong, D., & Doorduijn, J. (2019). Rituximab in patients with primary CNS lymphoma (HOVON 105/ALLG NHL 24): a randomised, open-label, phase 3 intergroup study. Lancet Oncology, 20(2), 216-228. https://doi.org/10.1016/s1470-2045(18)30747-2

@article{bf84eb7071024601b22f4bdacc84e08f,

title = "Rituximab in patients with primary CNS lymphoma (HOVON 105/ALLG NHL 24): a randomised, open-label, phase 3 intergroup study",

author = "Jacoline Bromberg and S Issa and Katerina Bakunina and MC Minnema and T Seute and M Durian and G Cull and HC Schouten and WBC Stevens and JM Zijlstra and JW Baars and M Nijland and KD Mason and A Beeker and {van den Bent}, Martin and M Beijert and M Gonzales and D Jong and Jeanette Doorduijn",

year = "2019",

doi = "10.1016/s1470-2045(18)30747-2",

language = "Undefined/Unknown",

volume = "20",

pages = "216--228",

journal = "The Lancet Oncology",

issn = "1470-2045",

publisher = "Lancet Publishing Group",

number = "2",

}

Bromberg, J, Issa, S, Bakunina, K, Minnema, MC, Seute, T, Durian, M, Cull, G, Schouten, HC, Stevens, WBC, Zijlstra, JM, Baars, JW, Nijland, M, Mason, KD, Beeker, A, van den Bent, M, Beijert, M, Gonzales, M, Jong, D & Doorduijn, J 2019, 'Rituximab in patients with primary CNS lymphoma (HOVON 105/ALLG NHL 24): a randomised, open-label, phase 3 intergroup study', Lancet Oncology, vol. 20, no. 2, pp. 216-228. https://doi.org/10.1016/s1470-2045(18)30747-2

TY - JOUR

T1 - Rituximab in patients with primary CNS lymphoma (HOVON 105/ALLG NHL 24): a randomised, open-label, phase 3 intergroup study

AU - Bromberg, Jacoline

AU - Issa, S

AU - Bakunina, Katerina

AU - Minnema, MC

AU - Seute, T

AU - Durian, M

AU - Cull, G

AU - Schouten, HC

AU - Stevens, WBC

AU - Zijlstra, JM

AU - Baars, JW

AU - Nijland, M

AU - Mason, KD

AU - Beeker, A

AU - van den Bent, Martin

AU - Beijert, M

AU - Gonzales, M

AU - Jong, D

AU - Doorduijn, Jeanette

PY - 2019

Y1 - 2019

U2 - 10.1016/s1470-2045(18)30747-2

DO - 10.1016/s1470-2045(18)30747-2

M3 - Article

SN - 1470-2045

VL - 20

SP - 216

EP - 228

JO - The Lancet Oncology

JF - The Lancet Oncology

IS - 2

ER -